ANIX is trading at $2.88 (-5.57%) following a sell the news reaction to its latest ovarian cancer CAR-T trial update.
- The company reported that the trial has advanced to its highest dose level to date with no dose-limiting toxicities and positive survival data.
- The decline appears to be driven by profit-taking and broader market weakness, with the NASDAQ Composite down 1.41% adding pressure to small-cap biotech shares.